As the world continues to grapple with the COVID-19 pandemic, the importance of biotechnology has become more apparent than ever before. Biotechnology companies have been at the forefront of developing treatments and vaccines to combat the virus, and as a result, the industry has seen a surge in demand and interest. With this in mind, many investors are looking to invest in biotechnology shares in 2022.

Here are some biotechnology shares that investors may want to consider for 2022:

1. Moderna (MRNA): Moderna is a biotechnology company that develops messenger RNA (mRNA) therapeutics and vaccines. The company made headlines in 2020 when it developed one of the first COVID-19 vaccines that was authorized for emergency use. Moderna’s share price has more than tripled since the beginning of 2020 and is expected to continue to rise in 2022 as the company works on developing new mRNA therapies.
2. Regeneron Pharmaceuticals (REGN): Regeneron Pharmaceuticals is a biotechnology company that develops medicines for serious medical conditions, including cancer and eye diseases. The company’s stock has been on the rise since 2020, thanks in part to its COVID-19 antibody cocktail, which was authorized for emergency use in the United States. Regeneron has also been working on developing treatments for other diseases and is expected to continue to see growth in 2022.
3. Vertex Pharmaceuticals (VRTX): Vertex Pharmaceuticals is a biotechnology company that develops medicines for the treatment of cystic fibrosis and other serious diseases. The company’s stock has been on the rise since 2020, thanks to its development of new treatments for cystic fibrosis. Vertex is expected to continue to see growth in 2022 as it works on developing new treatments for other diseases.
4. Gilead Sciences (GILD): Gilead Sciences is a biotechnology company that develops medicines for the treatment of HIV, hepatitis, and other serious diseases. The company made headlines in 2020 when its antiviral drug, remdesivir, was authorized for emergency use in the treatment of COVID-19. Gilead is expected to continue to see growth in 2022 as it works on developing new treatments for HIV and other diseases.
5. Amgen (AMGN): Amgen is a biotechnology company that develops medicines for the treatment of cancer, kidney disease, and other serious medical conditions. The company’s stock has been on the rise since 2020, thanks in part to its acquisition of Five Prime Therapeutics, a biotechnology company that develops treatments for cancer. Amgen is expected to continue to see growth in 2022 as it works on developing new treatments for cancer and other diseases.

As with any investment, it’s important to do your research and consider your financial goals and risk tolerance before investing in biotechnology shares. While the biotechnology industry has seen a surge in demand and interest in the wake of the COVID-19 pandemic, there are always risks and uncertainties associated with investing in any stock. It’s important to speak with a financial advisor to determine if investing in biotechnology shares is right for you.